These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30407547)

  • 1. Effect of in vivo post-translational modifications of the HMGB1 protein upon binding to platinated DNA: a molecular simulation study.
    Lv WL; Arnesano F; Carloni P; Natile G; Rossetti G
    Nucleic Acids Res; 2018 Dec; 46(22):11687-11697. PubMed ID: 30407547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational metallomics of the anticancer drug cisplatin.
    Calandrini V; Rossetti G; Arnesano F; Natile G; Carloni P
    J Inorg Biochem; 2015 Dec; 153():231-238. PubMed ID: 26490711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Interactions of High-Mobility Group of Protein Domain B1 with DNA Adducts Generated by Platinum Anticancer Molecules Using In Silico Approaches.
    Misra G; Gupta S; Jabalia N
    Interdiscip Sci; 2018 Sep; 10(3):476-485. PubMed ID: 27900730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.
    Park S; Lippard SJ
    Biochemistry; 2011 Apr; 50(13):2567-74. PubMed ID: 21355578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes.
    Brabec V; Kasparkova J; Kostrhunova H; Farrell NP
    Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox-sensitive structural change in the A-domain of HMGB1 and its implication for the binding to cisplatin modified DNA.
    Wang J; Tochio N; Takeuchi A; Uewaki J; Kobayashi N; Tate S
    Biochem Biophys Res Commun; 2013 Nov; 441(4):701-6. PubMed ID: 24427810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
    Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
    Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Click Chemistry-Based Force Spectroscopy Revealed Enhanced Binding Dynamics of Phosphorylated HMGB1 to Cisplatin-DNA.
    Liu Y; Song D; Li S; Guo Z; Zheng P
    J Am Chem Soc; 2024 May; 146(19):13126-13132. PubMed ID: 38696488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding interaction of HMGB4 with cisplatin-modified DNA.
    Park S; Lippard SJ
    Biochemistry; 2012 Aug; 51(34):6728-37. PubMed ID: 22901013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of PKC phosphorylation on the "architectural" properties of HMGB1 protein.
    Ugrinova I; Zlateva S; Pasheva E
    Mol Biol Rep; 2012 Nov; 39(11):9947-53. PubMed ID: 22740141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin adducts on a GGG sequence within a DNA duplex studied by NMR spectroscopy and molecular dynamics simulations.
    Téletchéa S; Skauge T; Sletten E; Kozelka J
    Chemistry; 2009 Nov; 15(45):12320-37. PubMed ID: 19813235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
    Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
    Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Characteristics of High-Mobility Group Proteins HMGB1 and HMGB2 and Their Interaction with DNA.
    Starkova TY; Polyanichko AM; Artamonova TO; Tsimokha AS; Tomilin AN; Chikhirzhina EV
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of cisplatin binding on nucleosome structure and dynamics.
    Todd RC; Lippard SJ
    Chem Biol; 2010 Dec; 17(12):1334-43. PubMed ID: 21168769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding modes of Bcl-2 homology 3 (BH3) peptides with anti-apoptotic protein A1 and redesign of peptide inhibitors: a computational study.
    Chen Y; Wang J; Zhang J; Wang W
    J Biomol Struct Dyn; 2018 Nov; 36(15):3967-3977. PubMed ID: 29137527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
    Malina J; Natile G; Brabec V
    Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Recognition of Platinated DNA from Chromosomal HMGB1.
    Nguyen TH; Rossetti G; Arnesano F; Ippoliti E; Natile G; Carloni P
    J Chem Theory Comput; 2014 Aug; 10(8):3578-84. PubMed ID: 26588321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
    Jung Y; Lippard SJ
    Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.